It has been a busy year for our firm’s Lipitor litigation team. These lawyers have investigated thousands of claims involving women who took the drug to prevent cardiovascular events, but later developed Type 2 diabetes. At the beginning of the year, the Plaintiffs’ Steering Committee (PSC) in the multidistrict litigation (MDL) disclosed a total of 14 experts to testify on various topics including the warning label, epidemiology, diabetes, and whether Lipitor provided a benefit for women. Several cases were also selected for bellwether trials. By mid-August, all of the Plaintiff and Defense experts, as well as the Plaintiffs and their case-specific witnesses, had been deposed and discovery was completed. This was a monumental effort by all of the firms and lawyers involved, including Frank Woodson from our firm.
In late September, U.S. District Judge Richard Gergel of Charleston, S.C., held two full days of hearings on the admissibility of the expert testimony offered by the parties. Additional hearings were held on Oct. 22. Additionally, you may recall from previous updates that the first trial was scheduled for November 2015. Unfortunately, Judge Gergel had to move this trial date to January 2016 due to his criminal docket, which takes precedence over civil trials. To date, Judge Gergel has not issued any rulings based on September and October hearings and we eagerly await his decisions. If you need information relating to this litigation, contact Frank Woodson in our firm’s Mass Torts Section, at 800-898-2034.